SalaryGuide
AboutPricingFor Employers

Marketing jobs

1 marketing jobs

Exelixis logo
3 months ago

Associate Marketing Director, Zanzalintinib CRC Launch – Promotions

Exelixis

Alameda, CA (On-site)Full time$179K/yr – $253K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

1 jobs
Exelixis logo

Associate Marketing Director, Zanzalintinib CRC Launch – Promotions

Exelixis

Alameda, CA (On-site)

$179K/yr - $253K/yrIn-houseFull-timeMid level9+ years exp.
3 months ago
Exelixis logo
Exelixis

Associate Marketing Director, Zanzalintinib CRC Launch – Promotions

Alameda, CA (On-site)

$179K/yr – $253K/yrMid Level9+ years expFull time

Posted 3 months ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Lead US pharma marketing for Zanza in mCRC, shaping messaging, budget, and cross-functional promotion.

  • Must-have: Advanced degree with 9+ years in product marketing or launches in pharma/biotech, plus regulatory awareness.
  • Standout: Oncology/patient-marketing exposure and cross-functional leadership across sales, regulatory, and market planning.

Job Description

Responsibilities

  • Support the development of US marketing tactical plans for new approval readiness and ongoing promotional execution of Zanza in mCRC
  • Ensure successful execution of compelling promotional tactics for US HCPs across personal and non-personal channels
  • Develop and align messaging platform and tactical rollout with brand objectives and strategies
  • Ensure key brand messages and materials are effectively communicated at sales meetings
  • Support management of the promotions budget, establish goals and metrics, and measure performance
  • Collaborate effectively with cross-functional partners, including field sales, sales training, market planning, and regulatory/compliance
  • Collaborate with the Patient/APP Marketing Team to develop promotional materials targeting patients, caregivers, and Advanced Practice Providers
  • Manage key vendor relationships, including the promotional agency of record
  • Foster trust and a strong culture across the broader marketing and sales teams and with partners throughout the organization
  • Ensure compliance with all laws, regulations, and policies that govern Exelixis conduct

Requirements

  • Master’s degree in related discipline and 9 years of related experience; or
  • BS/BA degree in related discipline and at least 11 years of related experience; or
  • Equivalent combination of education and experience
  • Experience in product marketing, field sales or market research/analysis in the pharmaceutical or biotech industries
  • Pharmaceutical Marketing
  • Knowledge, Skills And Abilities: Advanced prioritization skills and ability to handle multiple projects
  • Knowledge, Skills And Abilities: Comprehensive ability to collaborate with multiple organizational stakeholders
  • Knowledge, Skills And Abilities: Advanced talent for blending innovation with pragmatic execution
  • Knowledge, Skills And Abilities: Intermediate skills to network internally and externally
  • Knowledge, Skills And Abilities: Advanced ability to draw insight from market research, the sales force, and other sources to optimize messaging, tactical plans, and promotional activities
  • Knowledge, Skills And Abilities: Advanced strategic thinking, initiative and creativity
  • Knowledge, Skills And Abilities: Advanced track record for consistently meeting or exceeding financial and/or other quantitative targets, as well as qualitative goals
  • Knowledge, Skills And Abilities: Advanced presentation, verbal and written communication skills
  • Knowledge, Skills And Abilities: Advanced understanding of FDA Regulations of pharmaceutical drug promotions and experience with Legal, Medical and Regulatory review process
  • - Master’s degree in related discipline and 9 years of related experience; or - BS/BA degree in related discipline and at least 11 years of related experience; or - Equivalent combination of education and experience
  • - Experience in product marketing, field sales or market research/analysis in the pharmaceutical or biotech industries
  • - Pharmaceutical Marketing
  • - Product launch experience strongly preferred
  • - Oncology experience strongly preferred
  • - Patient Marketing, advocacy relations, public relations, digital marketing and sales experience are a plus

Preferred

  • Product launch experience strongly preferred
  • Oncology experience strongly preferred
  • Patient Marketing, advocacy relations, public relations, digital marketing and sales experience are a plus

Benefits

  • In addition to the base salary, as part of our Total Rewards program, Exelixis offers comprehensive employee benefits package, including a 401k plan with generous company contributions, group medical, dental and vision coverage, life and disability insurance, and flexible spending accounts.
Exelixis logo

Exelixis

2.0 Glassdoor

Every Exelixis employee is united in an ambitious cause: to transform science into new treatments that give cancer patients and their families hope for the future. In this pursuit, we know our employees are our most valuable asset. As a diverse, growing team, everyone at Exelixis plays a role in advancing our mission through our innovative drug discovery, development and commercialization efforts. We take pride in our shared purpose, knowing the magnitude of our impact expands with every medicine we create and every form of cancer tumor type we treat.After operating in the challenging biotech sector for nearly three decades, we've evolved into a multi-platform cancer company with a proven track record of resiliency in the face of adversity. The success of our flagship commercial product set us up on our journey to discover and develop next-generation cancer treatments, driven by our relentless pursuit of results for the patients we serve. Cancer is our cause. Make it yours, too. Please see our Community Guidelines: bit.ly/4iBzJU0For more information about Exelixis, please visit www.exelixis.com, follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.

Founded in 1994
Alameda, California, USA
1.5K employees (92 in marketing)
www.exelixis.com
11% recommend to a friend
9% CEO approval

Traffic Signals

Monthly Visitors
37.4K
Monthly Google Ads Budget
$10.2K
Traffic Source Mix
Search
59.3%
Direct
33.2%
Referral
6.3%
Social
0.5%
Paid
0.7%

Headcount Trend

Current headcount: ~1.5K

Marketing Team

Marketing Team Size
86 (6% of company)
Median Career Experience
21 years
Median Tenure
4.3 years
Marketing Roles Posted (Last 30 Days)
1

People

Marketing Leadership

Vishal Kapur
Vishal Kapur
Vice President, Head of Franchise Marketing
At the company for 2 years 2 months
Chris Summers
Chris Summers
Vice President, Marketing - GU Cancers
At the company for 5 years 4 months
Jared Caldwell
Jared Caldwell
Vice President. Head of GI Marketing
At the company for 10 years 8 months
Joseph Quadraccia
Joseph Quadraccia
Senior Vice President Marketing
At the company for 8 years 7 months

Funding

Total Funding
$514M
Last Raise
$135M
Post IPO Equity, 11 years ago

Funding History

  • Jul 2015
    Post IPO Equity • $135M
  • Feb 2012
    Post IPO Equity • $65M
  • Jun 2010
    Post IPO Debt • $160M

Recent News

Why Is Exelixis (EXEL) Up 9% Since Last Earnings Report?
Dec 4, 2025 • Yahoo Finance
Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025
Dec 3, 2025 • Yahoo Finance
Merck and Exelixis reveal their combo study | ApexOnco - Clinical Trials news and analysis
Nov 19, 2025 • Oncology Pipeline
Exelixis Hits 80-Plus Relative Strength Rating Benchmark
Nov 12, 2025 • Investor's Business Daily
Exelixis at Guggenheim Conference: Strategic Growth in Oncology
Nov 10, 2025 • Investing.com
Exelixis (EXEL): Earnings Growth Accelerates to 72%, Reinforcing Bullish Market Narratives
Nov 6, 2025 • simplywall.st
Exelixis Sees Its Composite Rating Rise To 97
Nov 6, 2025 • Investor's Business Daily
Exelixis: The STELLAR Win Is A Mixed Bag, But Things Look Positive Still
Nov 6, 2025 • Seeking Alpha
Exelixis (EXEL) Profit Margins Jump to 27%, Reinforcing Bullish Outlook on Accelerating Earnings
Nov 5, 2025 • Yahoo Finance
Exelixis Inc (EXEL) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Nov 5, 2025 • Yahoo Finance
Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Nov 4, 2025 • Business Wire
Exelixis, Inc. Q3 Profit Increases, Beats Estimates
Nov 4, 2025 • Nasdaq
Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Nov 4, 2025 • Yahoo Finance
Earnings call transcript: Exelixis beats Q3 2025 earnings expectations
Nov 4, 2025 • Investing.com
Earnings call transcript: Exelixis Q2 2025 sees solid revenue growth
Nov 2, 2025 • Investing.com
Exelixis, Inc. (EXEL) Gets Upgraded to Outperform from Market Perform by Leerink Partners
Oct 28, 2025 • Yahoo Finance
Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again
Oct 27, 2025 • Yahoo Finance
Exelixis (EXEL): Assessing Valuation After STELLAR-303 Trial Results and Market Reaction
Oct 22, 2025 • Yahoo Finance
Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
Oct 21, 2025 • Business Wire
RBC Capital Reiterates Exelixis (EXEL) Sector Perform Recommendation
Oct 21, 2025 • Nasdaq
Exelixis (EXEL) Loses 12% on Cancer Treatment Trial Results
Oct 21, 2025 • Yahoo Finance
Exelixis’ Kinase Blocker Sets ‘New Survival Bar’ in Third-Line Colorectal Cancer, Opening Road to FDA
Oct 21, 2025 • BioSpace
Exelixis plans NDA for zanzalintinib on colorectal cancer data
Oct 20, 2025 • BioWorld MedTech
ESMO25: Exelixis shares fall as colorectal cancer drug hopeful shows mixed picture
Oct 20, 2025 • FirstWord Pharma
ESMO: Exelixis 'franchise molecule' reduces death risk by 20% in Stivarga comparison trial
Oct 20, 2025 • Fierce Biotech
Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet
Oct 20, 2025 • Business Wire
Exelixis shares dip on colorectal cancer data
Oct 20, 2025 • BioPharma Dive
ESMO 2025 – no starring role for Exelixis’s Cabometyx follow-on | ApexOnco - Clinical Trials news and analysis
Oct 20, 2025 • Oncology Pipeline
Exelixis stock holds Buy rating at Truist despite limited STELLAR-303 impact
Oct 20, 2025 • Investing.com
Why Is Cancer Focused Exelixis Stock Falling On Monday? - Exelixis (NASDAQ:EXEL)
Oct 20, 2025 • Benzinga
Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX
Oct 18, 2025 • Business Wire
Is Now the Time to Reassess Exelixis After 50% Rally and FDA Filing News?
Oct 10, 2025 • simplywall.st
Morgan Stanley Maintains Overweight Rating For Exelixis, Inc. (EXEL), Price Target Raised To $50
Sep 26, 2025 • Yahoo Finance
Exelixis at Bernstein Forum: Oncology Focus and Strategic Growth
Sep 24, 2025 • Investing.com
Exelixis stock price target lowered to $35 at UBS on Zanza concerns
Sep 22, 2025 • Investing.com
The Bull Case For Exelixis (EXEL) Could Change Following Expanded Collaboration With Adagene’s SAFEbody Platform
Sep 21, 2025 • simplywall.st
Could Access to SAFEbody Technology Shift Exelixis (EXEL) Pipeline Strategy in Oncology?
Sep 18, 2025 • Yahoo Finance
Exelixis at H.C. Wainwright: Strategic Growth and Innovation
Sep 10, 2025 • Investing.com
Exelixis at Morgan Stanley Conference: Oncology Growth and Strategic Focus
Sep 9, 2025 • Investing.com
Exelixis (EXEL): Evaluating Valuation After Phase 3 Study Halt, Revenue Miss, and Legal Investigation News
Sep 8, 2025 • simplywall.st
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
Sep 8, 2025 • Yahoo Finance
Exelixis Appoints Longtime Veteran Dana T. Aftab as Head of R&D
Sep 5, 2025 • Yahoo Finance
Exelixis shuttering Pennsylvania site, laying off 130 employees
Sep 4, 2025 • Seeking Alpha
Exelixis at Wells Fargo Conference: Strategic Growth and Innovation
Sep 3, 2025 • Investing.com
Transcript : Exelixis, Inc. Presents at Wells Fargo 20th Annual Healthcare Conference 2025, Sep-03-2025 12
Sep 3, 2025 • MarketScreener
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with the Schall Law Firm
Sep 2, 2025 • Business Wire
UPDATED: Exelixis to lay off 130 employees, shut down Pennsylvania site in post-pandemic downsizing
Aug 29, 2025 • Fierce Biotech
Exelixis Announces Appointment Of Dana T. Aftab, Ph.D. As Executive Vice President, Research And Development
Aug 29, 2025 • Reuters
Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development
Aug 29, 2025 • Morningstar.com
Exelixis, Inc. Appoints Dana T. Aftab as Its Executive Vice President, Research and Development
Aug 29, 2025 • MarketScreener
After Trump announcement, Intel among several companies to make Bay Area job cuts
Aug 29, 2025 • East Bay Times
Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development
Aug 29, 2025 • MarketScreener
Exelixis announces appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development
Aug 29, 2025 • MarketScreener
Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development
Aug 29, 2025 • Business Wire
Exelixis closing King of Prussia operations, eliminating 130 jobs
Aug 28, 2025 • Seattle TechFlash
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September 2025
Aug 28, 2025 • BioSpace
A California cancer biotech is closing its King of Prussia site and laying off 130 people
Aug 28, 2025 • The Philadelphia Inquirer
Exelixis Lays Off 130 as Pennsylvania Site Closes Down
Aug 28, 2025 • BioSpace
Why Is Exelixis (EXEL) Up 3.8% Since Last Earnings Report?
Aug 27, 2025 • Yahoo Finance
Exelixis closes up shop in Pennsylvania, cuts 130 jobs
Aug 27, 2025 • FirstWord Pharma
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
Aug 27, 2025 • MarketScreener
Exelixis: RCC Stronghold, NET Launch, And A CRC Readout That Matters (NASDAQ:EXEL)
Aug 25, 2025 • Seeking Alpha
Sonoma Biotherapeutics Appoints Lisa Taylor Ash, JD, as Chief Legal Officer
Aug 25, 2025 • Business Wire
Is Exelixis Still Attractive After Recent 13% Pullback and Strong Cash Flow Growth?
Aug 22, 2025 • Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
Aug 22, 2025 • Morningstar.com
Does Exelixis Offer Value After Recent Stock Drop and Earnings Results?
Aug 21, 2025 • simplywall.st
VEGFR-2 Inhibitors Market Set to Transform Oncology Treatment Landscape by 2034 | DelveInsight
Aug 21, 2025 • PR Newswire UK
VEGFR-2 Inhibitors Market Set to Transform Oncology Treatment Landscape by 2034 | DelveInsight
Aug 21, 2025 • PR Newswire
Exelixis Gains 15.6% YTD: How Should You Play the Stock?
Aug 14, 2025 • Yahoo Finance
Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates
Aug 12, 2025 • Adagene Inc.
Exelixis, Inc. (EXEL) Under Investigation for Potential Securities Law Violations - Contact Levi & Korsinsky Today
Aug 12, 2025 • Newsfile
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Exelixis, Inc. - EXEL
Aug 9, 2025 • Morningstar.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Exelixis, Inc. - EXEL
Aug 9, 2025 • Pomerantz LLP
Stocks With Rising Relative Price Strength: Exelixis
Aug 6, 2025 • Investor's Business Daily
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
Aug 6, 2025 • PR Newswire
Exelixis, Inc. : The cure to cancer?
Aug 5, 2025 • MarketScreener
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
Aug 5, 2025 • Pomerantz LLP
Don't Overlook Exelixis (EXEL) International Revenue Trends While Assessing the Stock
Aug 4, 2025 • Yahoo Finance
Novo Nordisk, United Parcel Service, And Moderna Are Among Top 10 Large Cap Losers Last Week (July 28-August 1): Are The Others In Your Portfolio?
Aug 3, 2025 • Benzinga.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
Aug 1, 2025 • Pomerantz LLP
Exelixis: Zanzalintinib Sees Mixed Progress, Cabozantinib Grinds Upwards (NASDAQ:EXEL)
Jul 31, 2025 • Seeking Alpha
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
Jul 31, 2025 • PR Newswire
Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes"
Jul 30, 2025 • Yahoo Finance
Other news to note for July 30, 2025
Jul 30, 2025 • BioWorld Financial Watch
Exelixis (EXEL) Tumbles 16.8% as Q2 Earnings Disappoint
Jul 30, 2025 • Yahoo Finance
Exelixis Inc (EXEL) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Challenges
Jul 29, 2025 • Yahoo Finance
Exelixis leans on zanzalintinib as cabozantinib nears patent expiry
Jul 29, 2025 • S&P Global
Analyst Surprised By Exelixis Q2 Revenue Miss, Delays STELLAR-304 Readout, Halts STELLAR-305 Phase 3 Plans
Jul 29, 2025 • Benzinga.com
North American Morning Briefing: Stock Futures Rise as Investors Weigh Trade Talks, Earnings
Jul 29, 2025 • Morningstar.com
Whirlpool Posts Downbeat Earnings, Joins Harmonic, Stanley Black & Decker And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Jul 29, 2025 • Benzinga.com
Exelixis outlines continued cabozantinib growth and zanzalintinib pipeline acceleration as new launches drive 19% revenue increase
Jul 29, 2025 • Seeking Alpha
Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update
Jul 28, 2025 • Business Wire
Earnings call transcript: Exelixis beats EPS forecasts in Q2 2025
Jul 28, 2025 • Investing.com
Morgan Stanley Maintains a Buy on Exelixis (EXEL) With a $48 PT
Jul 28, 2025 • Yahoo Finance
Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update
Jul 28, 2025 • BioSpace
Metastatic Hormone Refractory Prostate Cancer Pipeline Market Research Report 2025 | In-depth Analysis of 180+ Companies and Over 200 Drugs in Development
Jul 25, 2025 • Research and Markets
Ipsen’s Cabometyx secures EC nod for neuroendocrine tumors
Jul 25, 2025 • Pharma Letter
Exelixis stock poised for Q2 beat on strong script growth, JMP says
Jul 24, 2025 • Investing.com
Ipsen granted EU nod for Exelixis-partnered cancer drug for neuroendocrine tumors
Jul 24, 2025 • Seeking Alpha
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
Jul 24, 2025 • BioSpace